Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialEurope PMCOpen access

Macrophage tumor necrosis factor-alpha deletion does not protect against obesity-associated metabolic dysfunction

Aladhami AK., Unger CA., Ennis SL., Altomare D., Ji H., Hope MC.

Randomized Controlled Trial with a reported sample of 16 on Type 2 Diabetes, published in FASEB J (2021) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
FASEB J (2021)
Reported sample size
16
Source database
Europe PMC
PMID
34131955
PMCID
PMC8716064
DOI
10.1096/fj.202100543rr
Citations
21

Abstract (original English)

The pro-inflammatory cytokine, tumor necrosis factor-alpha (TNF-α), has been suggested to be a key factor in the induction of obesity-associated metabolic dysfunction. However, the role that macrophage-derived TNF-α has on regulating metabolic perturbations in obesity is not completely understood. Therefore, we utilized the TNF-α Flox/Flox (F/F) , LyzMcre ± mouse model to determine the impact that macrophage TNF-α deletion has on the development of high-fat diet (HFD)-induced obesity. At 10 weeks of age, male littermates were randomly assigned to 1 of 4 groups: TNF-α F/F low-fat diet (TNF-α F/F LFD), TNF-α F/F, LyzMCre LFD, TNF-α F/F HFD, or TNF-α F/F, LyzMCre HFD (n = 16-28/group) and were fed their respective diets for 18 weeks. Body weight was assessed throughout the course of the experiment. Body composition, hepatic lipid accumulation, and metabolic outcomes were also examined. A microarray gene expression experiment was performed from RNA isolated from epididymal adipose tissue of the HFD-fed groups (n = 10/group) and results were verified via qRT-PCR for all groups. Macrophage-derived TNF-α deletion significantly reduced adipose tissue TNF-α gene expression and circulating TNF-α and downregulated genes linked to the toll-like receptor (TLR) and NFκB signaling pathways. However, macrophage TNF-α deletion had no effect on hindering the development of obesity, hepatic lipid

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
MacrophagesAnimalsMice, Inbred C57BLMice, KnockoutMiceInsulin ResistanceObesityInflammationTumor Necrosis Factor-alphaFemale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research